Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05539157 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Tumor
Malignant Solid Tumor

Interventions

DRUG: JCXH-211

Sponsor

Immorna Biotherapeutics, Inc.